Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 6 months to 65 years old at the time of giving consent.
• People with a type of blood cancer called acute myeloid leukemia (AML) whose cancer is in remission (first or later remission), with less than 5% abnormal cells in the bone marrow at the time of transplant.
• People with a type of blood cancer called acute lymphoblastic leukemia (ALL) who are in first remission and have features that make relapse more likely, or who are in a second or later remission, with less than 5% abnormal cells in the bone marrow.
• People with other types of acute leukemia of mixed or unclear type, in remission with less than 5% abnormal cells in the bone marrow.
• People with chronic myeloid leukemia (CML), except those in refractory blast crisis; people in the first chronic phase must have already tried or been unable to tolerate a standard targeted therapy called a tyrosine kinase inhibitor.
• People with certain bone marrow disorders (MDS or MPD, but not myelofibrosis), with less than 10% abnormal cells in the bone marrow and sufficient white blood cell levels at assessment.
• People with certain types of non-Hodgkin lymphoma (NHL) at high risk of returning or worsening, who meet specific remission criteria on imaging (confirm with trial site).
• People with a rare blood cancer called BPDCN whose cancer is in remission.
• Adults aged over 18 with a performance (physical wellbeing) score of 70% or above on the Karnofsky scale; children 18 and under with a score of 50% or above on the Lansky scale.
• People whose kidneys, liver, lungs, and heart are functioning well enough to meet specific test thresholds (confirm exact values with trial site).
• People whose blood protein (albumin) levels are above a minimum threshold.
• Adults over 18 with a transplant health score (HCT-CI) of 5 or below.
• People for whom a suitably matched umbilical cord blood (UCB) unit is available.

Who may not be able to join:

• People diagnosed with myelofibrosis or another cancer causing moderate to severe scarring of the bone marrow.
• People who still have cancer involvement in the fluid or imaging of the brain and spine at the time of screening.
• People who have received certain immunotherapy drugs called checkpoint inhibitors within the past 12 months.
• People who have had two previous stem cell transplants of any kind.
• People who had a stem cell transplant using their own cells (autologous) within the past 12 months.
• People who have previously had a stem cell transplant using someone else's cells (allogeneic).
• People who have had prior radiation treatment in a way that would make it unsafe to receive the low-dose whole-body radiation used in this trial, in the opinion of a radiation specialist.
• People with an active infection that is not under control at the time of transplant.
• People living with HIV.
• People whose physical wellbeing or organ function does not meet the required levels.
• People who are pregnant or breastfeeding.
• People, or their guardians, who are unable to give informed consent or are unable to follow the full treatment plan, including follow-up visits and research tests.

Important: Always verify eligibility with the trial site directly before applying.